spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  hypertriglyceridemia 

 HSMN NewsFeed - 19 Jul 2024
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Jan 2023
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Aug 2020
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 14 Aug 2019
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Jun 2018
ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 8 Feb 2018
ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Sep 2017
Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 20 Jul 2016
Mylan Launches Generic Crestor(R) Tablets
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 1 Sep 2015
Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 18 Mar 2015
Nimbus Therapeutics Raises $43 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 2 Jul 2014
Alnylam Elects Amy Schulman to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 May 2014
FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Feb 2014
Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Nov 2013
Catabasis Closes $32.4 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Oct 2013
Pfizer Inc. Announces FDA Approval of DUAVEE(TM) (conjugated estrogens/ bazedoxifene) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis [1]
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jul 2013
American Association Of Clinical Endocrinologists (AACE) Endorses Measurement Of Low-Density Lipoprotein Particle (LDL-P) Number
Diagnostics Endocrinology
 HSMN NewsFeed - 24 Jan 2013
Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2012
Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE
Biopharmaceuticals
 HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Dec 2011
Catabasis Pharmaceuticals Announces $8 Million Series A Extension Financing
Biopharmaceuticalas Venture Capital
 HSMN NewsFeed - 25 Oct 2011
Aegerion Pharmaceuticals Appoints Craig E. Fraser as President, U.S.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jul 2011
Aegerion Pharmaceuticals Announces Appointment of Paul G. Thomas to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals
 HSMN NewsFeed - 14 Mar 2011
Omthera Pharmaceuticals Initiates Pivotal Phase III EVOLVE Trial for Epanova in Patients with Very High Triglycerides
Biopharmaceuticals
 HSMN NewsFeed - 15 Feb 2011
Aegerion Pharmaceuticals Appoints Diane L. Tribble, Ph.D., M.M.Sc., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2011
Aegerion Pharmaceuticals Appoints Martha J. Carter as Chief Regulatory Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2010
Omthera Pharmaceuticals, Inc. Closes a $6.5M Series A led by Sofinnova Partners to Advance Epanova, a Prescription Omega 3 Therapy
Biopharmaceuticals Cardiology Venture Capital
 HSMN NewsFeed - 6 Nov 2009
Amarin Appoints John F. Thero as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Oct 2009
Amarin Announces Changes to Its Board and Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Feb 2009
Oscient Pharmaceuticals Restructures Commercial Organization
Biopharmaceuticals
 HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2008
Amarin Appoints Dr. Paresh Soni as SVP and Head of Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Aug 2008
LifeCycle Pharma Sells Fenoglide(TM) Royalty Stream to Cowen Healthcare Royalty Partners for up to USD 105 Million Including an Upfront Payment of USD 29 Million
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 14 Aug 2008
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
Biopharmaceuticals
 HSMN NewsFeed - 30 Jul 2008
Oscient Pharmaceuticals Promotes Mark A. Glickman to Senior Vice President, Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2008
Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 1 May 2008
XenoPort Appoints Vincent J. Angotti as Chief Commercialization Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Feb 2008
Sciele Pharma and LifeCycle Pharma Announce U.S. Market Launch of Fenoglide(TM)
Biopharmaceuticals
 HSMN NewsFeed - 21 Feb 2008
LifeCycle Pharma Launches Its First Product in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Nov 2007
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Nov 2007
New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Aug 2007
Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Biopharmaceuticals
 HSMN NewsFeed - 23 Aug 2007
Oscient Pharmaceuticals Names Aaron D. Berg Vice President of Marketing and Mark A. Glickman Vice President of Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2007
Sciele Pharma and Lifecycle Pharma Announce FDA Approval of New Formulation of Fenofibrate in 120 Mg. and 40 Mg. Dosage Strengths
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 13 Jun 2007
Bradley Pharmaceuticals Announces Launch of Elestrin(TM)
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2007
July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2007
Data Presented at ASCO Showed TORISEL Significantly Increased Quality-Adjusted Survival for Patients With Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2007
FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Apr 2007
Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 2 Mar 2007
Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in Canada
Biopharmacetuicals
 HSMN NewsFeed - 22 Feb 2007
New Treatment Guidelines for Community-Acquired Pneumonia Highlight Utility of FACTIVE Tablets
Biopharmaceuticals
 HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jan 2007
Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE Tablets
Biopharmaceuticals
 HSMN NewsFeed - 29 Dec 2006
Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG Life Sciences
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Dec 2006
Reliant Pharmaceuticals Submits New Data to FDA Supporting Use of Omacor(R) (Omega-3-Acid Ethyl Esters) With a Statin to Reduce High Triglycerides
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Nov 2006
FDA Accepts as "Complete Response" Oscient Pharmaceuticals' Submission Following FACTIVE Approvable Letter for Five-Day CAP
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Oct 2006
Data on FACTIVE(R) Tablets Short-Course Therapy in Patients with Co-Morbidities Presented at Annual Meeting of Infectious Diseases Society of America
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
Oscient Pharmaceuticals and Pfizer, S.A. de C.V. Announce Launch of FACTIVE(R) Tablets in Mexico
Biopharmaceuticals
 HSMN NewsFeed - 22 Sep 2006
Oscient Pharmaceuticals Receives Approvable Letter from FDA for FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Sep 2006
Oscient Pharmaceuticals Announces Results of FDA Advisory Committee Meeting for FACTIVE Tablets for the Treatment of Acute Bacterial Sinusitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jul 2006
Abbott and AstraZeneca Announce Collaboration to Develop and Commercialize CRESTOR(R) and Next-Generation TriCor(R) (ABT-335) Fixed-Dose Combination
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Jun 2006
New Data Shows CRESTOR(R) Helped African American, Hispanic American and South Asian American Patients Significantly Lower LDL-C and Achieve Cholesterol Goals
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2006
CRESTOR Helped More Patients Reach Goal in MERCURY II Study
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 34

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 34 additional stories matching:
hypertriglyceridemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.